These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 20722574)

  • 1. Orlistat and calcium oxalate crystalluria: an association that needs consideration.
    Ahmed MH
    Ren Fail; 2010; 32(8):1019-21. PubMed ID: 20722574
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term pharmacotherapy for obesity.
    Klein S
    Obes Res; 2004 Dec; 12 Suppl():163S-6S. PubMed ID: 15687412
    [TBL] [Abstract][Full Text] [Related]  

  • 3. X-PERT: weight reduction with orlistat in obese subjects receiving a mildly or moderately reduced-energy diet: early response to treatment predicts weight maintenance.
    Toplak H; Ziegler O; Keller U; Hamann A; Godin C; Wittert G; Zanella MT; Zúñiga-Guajardo S; Van Gaal L
    Diabetes Obes Metab; 2005 Nov; 7(6):699-708. PubMed ID: 16219013
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Orlistat-induced oxalate nephropathy may be dose-independent and present as a late manifestation.
    Dossabhoy NR; McRight S; Sangha B; Khan S; Adgeh C
    J La State Med Soc; 2013; 165(5):283-5. PubMed ID: 24350530
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of metabolic effects of orlistat and sibutramine treatment in Type 2 diabetic obese patients.
    Derosa G; Cicero AF; Murdolo G; Ciccarelli L; Fogari R
    Diabetes Nutr Metab; 2004 Aug; 17(4):222-9. PubMed ID: 15575343
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Is there a link between calcium oxalate crystalluria, orlistat and acute tubular necrosis?
    Karamadoukis L; Ludeman L; Williams AJ
    Nephrol Dial Transplant; 2008 May; 23(5):1778-9. PubMed ID: 18272781
    [No Abstract]   [Full Text] [Related]  

  • 7. Orlistat maintains biliary lipid composition and hepatobiliary function in obese subjects undergoing moderate weight loss.
    Trouillot TE; Pace DG; McKinley C; Cockey L; Zhi J; Häeussler J; Guerciolini R; Showalter R; Everson GT
    Am J Gastroenterol; 2001 Jun; 96(6):1888-94. PubMed ID: 11421247
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acute oxalate nephropathy associated with orlistat, a gastrointestinal lipase inhibitor.
    Singh A; Sarkar SR; Gaber LW; Perazella MA
    Am J Kidney Dis; 2007 Jan; 49(1):153-7. PubMed ID: 17185156
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of orlistat on weight regain and cardiovascular risk factors following a very-low-energy diet in abdominally obese patients: a 3-year randomized, placebo-controlled study.
    Richelsen B; Tonstad S; Rössner S; Toubro S; Niskanen L; Madsbad S; Mustajoki P; Rissanen A
    Diabetes Care; 2007 Jan; 30(1):27-32. PubMed ID: 17192328
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nonrandomized trial of weight loss with orlistat, nutrition education, diet, and exercise in obese patients with CKD: 2-year follow-up.
    MacLaughlin HL; Cook SA; Kariyawasam D; Roseke M; van Niekerk M; Macdougall IC
    Am J Kidney Dis; 2010 Jan; 55(1):69-76. PubMed ID: 19926371
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term changes in blood pressure following orlistat and sibutramine treatment: a meta-analysis.
    Johansson K; Sundström J; Neovius K; Rössner S; Neovius M
    Obes Rev; 2010 Nov; 11(11):777-91. PubMed ID: 20025693
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Orlistat-induced oxalate nephropathy: an under-recognised cause of chronic kidney disease.
    Solomon LR; Nixon AC; Ogden L; Nair B
    BMJ Case Rep; 2017 Nov; 2017():. PubMed ID: 29133578
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Weight loss at a high cost: Orlistat-induced late-onset severe kidney disease.
    Buysschaert B; Aydin S; Morelle J; Hermans MP; Jadoul M; Demoulin N
    Diabetes Metab; 2016 Feb; 42(1):62-4. PubMed ID: 26454353
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety profile of orlistat: results of a prescription-event monitoring study.
    Acharya NV; Wilton LV; Shakir SA
    Int J Obes (Lond); 2006 Nov; 30(11):1645-52. PubMed ID: 16552401
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Orlistat, a gastrointestinal lipase inhibitor, in therapy of obesity with concomitant hyperlipidemia.
    Micić D; Ivković-Lazar T; Dragojević R; Jorga J; Stokić E; Hajduković Z
    Med Pregl; 1999; 52(9-10):323-33. PubMed ID: 10624380
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of orlistat for the treatment of overweight and obese patients in Ireland.
    Lacey LA; Wolf A; O'shea D; Erny S; Ruof J
    Int J Obes (Lond); 2005 Aug; 29(8):975-82. PubMed ID: 15852050
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Orlistat: hepatitis and oxalate nephropathy.
    Prescrire Int; 2012 Mar; 21(125):71. PubMed ID: 22428191
    [No Abstract]   [Full Text] [Related]  

  • 18. A randomized double-blind study comparing the efficacy and safety of orlistat versus placebo in obese patients with mild to moderate hypercholesterolemia.
    de Castro JJ; Dias T; Chambel P; Carvalheiro M; Correia LG; Guerreiro L; Marques O; Medina JL; Nobre E; Nunes JS; Pereiraa MC; Polónia J; Portugal J; Raimundo A; Ruas A; da Silva PM; Vasconcelos C; Reis JL; Teles AG
    Rev Port Cardiol; 2009 Dec; 28(12):1361-74. PubMed ID: 20301983
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An unusual complication of treatment with orlistat.
    Karamadoukis L; Shivashankar GH; Ludeman L; Williams AJ
    Clin Nephrol; 2009 Apr; 71(4):430-2. PubMed ID: 19356376
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Orlistat: a second look. At best, a minor adjunct to dietary measures.
    Prescrire Int; 2002 Feb; 11(57):10-2. PubMed ID: 11985367
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.